EXELIXIS, INC.
In the published model solve dated 2026-Q2, anchored at $57.94, EXELIXIS, INC. (EXEL) is priced for +1.3% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 26, 2026 from SEC EDGAR filings.
• One molecule carries this company: the 10-K states plainly that ⟦"Sales related to cabozantinib account for the majority of our revenues."⟧, and United States net product sales of the cabozantinib franchise were $555.0 million in the first quarter of 2026 alone [Source: Q1 2026 results release, May 5, 2026]. • The patent table is the risk register, and it is specific: the composition-of-matter patent covering cabozantinib expires in 2026, with the salt, formulation and method-of-treatment pate
Is EXEL overvalued? See what's priced in →
674 institutional managers reported holding EXEL in 13F filings for the quarter ended 2026-03-31. 89 opened new positions that quarter. Held by BlackRock, Vanguard Group, Renaissance Technologies, among others. On the short side, 30.6M shares were sold short as of the 2026-06-15 count, about 11% of shares outstanding (13.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
EXEL has cut its share count 17.8% over the past five years, spending $2.58B on repurchases. It pays no dividend. Cash returned over the past three years: $2.46B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at EXEL over the trailing three years: 2023: 1 buy totaling $2.60M; 2024: 3 buys totaling $12.67M; 2025: 1 buy totaling $1.19M. 18 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
EXEL's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-10 | +1.8% | -0.1% |
| 2023-08-02 | +3.2% | +7.0% |
| 2023-11-02 | -2.2% | +17.3% |
| 2024-05-01 | -7.6% | +0.1% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
EXEL's latest 8-K filings: 2026-09-11 (items 8.01); 2026-08-31 (items 8.01); 2026-08-05 (items 2.02, 9.01); 2026-05-29 (items 5.02, 5.07, 9.01); 2026-05-05 (items 2.02, 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 26, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.